Abstract
Anti-TNFalpha therapy is an effective treatment of Crohn's disease. There is an increased risk of infection, including atypical infection associated in infliximab treated patients. We report a case of a young man who developed Pneumocystisjiroveci pneumonia shortly after starting therapy with infliximab. Thus, although rare, prophylaxis against Pneumocystis jiroveci pneumonia might be considered when starting a treatment with infliximab, especially in patients receiving concomitant immunosuppressive agents.
Publication types
-
Case Reports
-
Duplicate Publication
MeSH terms
-
Adult
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use
-
Azathioprine / adverse effects*
-
Azathioprine / therapeutic use
-
Crohn Disease / drug therapy*
-
Gastrointestinal Agents / adverse effects*
-
Gastrointestinal Agents / therapeutic use
-
Humans
-
Immunosuppressive Agents / adverse effects*
-
Immunosuppressive Agents / therapeutic use
-
Infliximab
-
Male
-
Pneumocystis carinii / pathogenicity*
-
Pneumonia, Pneumocystis / chemically induced*
-
Tumor Necrosis Factor-alpha
Substances
-
Antibodies, Monoclonal
-
Gastrointestinal Agents
-
Immunosuppressive Agents
-
Tumor Necrosis Factor-alpha
-
Infliximab
-
Azathioprine